Protein Official symbol | ENO2 |
Aliases | ENO2 |
Chromosomal Location | 12 |
Length | 434 |
Uniprot ID | P09104 |
EC number | 4.2.1.11 |
Protein family Information(Pfam) | PF00113;PF03952; |
PDB id | 1TE6;2AKM;2AKZ;3UCC;3UCD;3UJE;3UJF;3UJR;3UJS;4ZA0;4ZCW;5EU9;5IDZ;5TD9;5TIJ; |
InterPro ID | IPR000941;IPR036849;IPR029017;IPR020810;IPR020809;IPR020811; |
dbSNP | None |
Protein 1 | Protein 2 | Combine Score |
---|---|---|
PGK1 | TPI1 | 0.9990000000000001 |
GPI | TPI1 | 0.9990000000000001 |
TPI1 | GAPDH | 0.9990000000000001 |
PGK1 | GAPDH | 0.998 |
ENO1 | TPI1 | 0.996 |
ENO1 | GAPDH | 0.995 |
PGAM1 | ENO3 | 0.9940000000000001 |
PKM | ENO1 | 0.993 |
PGAM1 | ENO1 | 0.993 |
PGK1 | ENO1 | 0.991 |
PGK1 | PGAM1 | 0.99 |
GPI | ENO1 | 0.99 |
ENO3 | PKM | 0.9890000000000001 |
GPI | PKM | 0.987 |
GPI | GAPDH | 0.986 |
PKLR | ENO3 | 0.985 |
ENO2 | PGAM1 | 0.9840000000000001 |
PKLR | ENO1 | 0.9840000000000001 |
GPI | ENO3 | 0.983 |
ENO3 | PGAM2 | 0.983 |
GPI | PKLR | 0.983 |
PGK1 | PGAM2 | 0.983 |
ENO2 | PKM | 0.981 |
ENO2 | PKLR | 0.98 |
PGAM2 | ENO1 | 0.978 |
BPGM | PGK1 | 0.973 |
ENO2 | GPI | 0.972 |
PKM | GAPDH | 0.9690000000000001 |
PGAM1 | TPI1 | 0.9690000000000001 |
BPGM | GAPDH | 0.968 |
BPGM | ENO1 | 0.9670000000000001 |
PKLR | PCK1 | 0.966 |
PKM | TPI1 | 0.9640000000000001 |
ENO2 | PGAM2 | 0.9640000000000001 |
ENO2 | ENO1 | 0.963 |
BPGM | ENO3 | 0.963 |
GPI | PGAM1 | 0.9620000000000001 |
ENO2 | ENO3 | 0.9620000000000001 |
ENO3 | ENO1 | 0.9620000000000001 |
ENO3 | TPI1 | 0.961 |
PKLR | PCK2 | 0.96 |
GPI | PGK1 | 0.9570000000000001 |
PKM | PCK2 | 0.955 |
ENO2 | TPI1 | 0.955 |
ENO2 | BPGM | 0.955 |
BPGM | PGAM2 | 0.9540000000000001 |
BPGM | MINPP1 | 0.9520000000000001 |
PKM | PCK1 | 0.95 |
GPI | PGAM2 | 0.95 |
PCK1 | ENO1 | 0.946 |
ENO2 | PGK1 | 0.945 |
SYP | CHGA | 0.945 |
ENO1 | PCK2 | 0.9440000000000001 |
PGK1 | PKM | 0.9440000000000001 |
PKLR | TPI1 | 0.941 |
ENO3 | PCK1 | 0.94 |
ENO3 | PCK2 | 0.94 |
ENO2 | PCK1 | 0.9390000000000001 |
PGK1 | ENO3 | 0.938 |
PGAM1 | PGAM2 | 0.935 |
ENO2 | PCK2 | 0.935 |
ENO2 | SYP | 0.927 |
ENO2 | CHGA | 0.925 |
GPI | BPGM | 0.922 |
PGAM2 | TPI1 | 0.915 |
ENO2 | GAPDH | 0.914 |
MINPP1 | PGAM1 | 0.9059999999999999 |
BPGM | PGAM1 | 0.905 |
MINPP1 | PGAM2 | 0.904 |
PGAM1 | GAPDH | 0.903 |
MINPP1 | ENO1 | 0.9 |
ENO2 | MINPP1 | 0.9 |
MINPP1 | ENO3 | 0.9 |
# | 5230 (PGK1) | 2821 (GPI) | 7167 (TPI1) | 2023 (ENO1) | 5223 (PGAM1) | 5315 (PKM) | 2027 (ENO3) | 5313 (PKLR) | 2026 (ENO2) | 5224 (PGAM2) | 669 (BPGM) | 5105 (PCK1) | 6855 (SYP) | 9562 (MINPP1) | 2597 (GAPDH) | 5106 (PCK2) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5230 (PGK1) | 1.00 | 0.31 | 0.47 | 0.48 | 0.43 | 0.55 | 0.18 | 0.46 | 0.45 | 0.15 | 0.15 | 0.38 | 0.39 | 0.14 | 0.47 | 0.41 |
2821 (GPI) | 0.31 | 1.00 | 0.81 | 0.36 | 0.45 | 0.36 | 0.20 | 0.20 | 0.40 | 0.27 | 0.27 | 0.17 | 0.31 | 0.15 | 0.33 | 0.36 |
7167 (TPI1) | 0.47 | 0.81 | 1.00 | 0.55 | 0.60 | 0.57 | 0.20 | 0.20 | 0.60 | 0.24 | 0.24 | 0.26 | 0.50 | 0.15 | 0.51 | 0.53 |
2023 (ENO1) | 0.48 | 0.36 | 0.55 | 1.00 | 0.52 | 0.70 | 1.00 | 0.20 | 0.72 | 0.13 | 0.13 | 0.27 | 0.45 | 0.13 | 0.51 | 0.55 |
5223 (PGAM1) | 0.43 | 0.45 | 0.60 | 0.52 | 1.00 | 0.53 | 0.20 | 0.20 | 0.53 | 0.71 | 0.64 | 0.24 | 0.44 | 0.15 | 0.48 | 0.48 |
5315 (PKM) | 0.55 | 0.36 | 0.57 | 0.70 | 0.53 | 1.00 | 0.20 | 1.00 | 0.57 | 0.15 | 0.15 | 0.26 | 0.48 | 0.14 | 0.54 | 0.52 |
2027 (ENO3) | 0.18 | 0.20 | 0.20 | 1.00 | 0.20 | 0.20 | 1.00 | 0.20 | 1.00 | 0.20 | 0.20 | 0.29 | 0.13 | 0.17 | 0.24 | 0.34 |
5313 (PKLR) | 0.46 | 0.20 | 0.20 | 0.20 | 0.20 | 1.00 | 0.20 | 1.00 | 0.20 | 0.20 | 0.20 | 0.17 | 0.13 | 0.17 | 0.40 | 0.20 |
2026 (ENO2) | 0.45 | 0.40 | 0.60 | 0.72 | 0.53 | 0.57 | 1.00 | 0.20 | 1.00 | 0.18 | 0.18 | 0.30 | 0.51 | 0.16 | 0.50 | 0.59 |
5224 (PGAM2) | 0.15 | 0.27 | 0.24 | 0.13 | 0.71 | 0.15 | 0.20 | 0.20 | 0.18 | 1.00 | 0.90 | 0.11 | 0.11 | 0.16 | 0.15 | 0.18 |
669 (BPGM) | 0.15 | 0.27 | 0.24 | 0.13 | 0.64 | 0.15 | 0.20 | 0.20 | 0.18 | 0.90 | 1.00 | 0.11 | 0.11 | 0.16 | 0.15 | 0.18 |
5105 (PCK1) | 0.38 | 0.17 | 0.26 | 0.27 | 0.24 | 0.26 | 0.29 | 0.17 | 0.30 | 0.11 | 0.11 | 1.00 | 0.24 | 0.11 | 0.23 | 0.55 |
6855 (SYP) | 0.39 | 0.31 | 0.50 | 0.45 | 0.44 | 0.48 | 0.13 | 0.13 | 0.51 | 0.11 | 0.11 | 0.24 | 1.00 | 0.10 | 0.41 | 0.43 |
9562 (MINPP1) | 0.14 | 0.15 | 0.15 | 0.13 | 0.15 | 0.14 | 0.17 | 0.17 | 0.16 | 0.16 | 0.16 | 0.11 | 0.10 | 1.00 | 0.15 | 0.16 |
2597 (GAPDH) | 0.47 | 0.33 | 0.51 | 0.51 | 0.48 | 0.54 | 0.24 | 0.40 | 0.50 | 0.15 | 0.15 | 0.23 | 0.41 | 0.15 | 1.00 | 0.46 |
5106 (PCK2) | 0.41 | 0.36 | 0.53 | 0.55 | 0.48 | 0.52 | 0.34 | 0.20 | 0.59 | 0.18 | 0.18 | 0.55 | 0.43 | 0.16 | 0.46 | 1.00 |
Protein Official symbol | Source Organism | Tissue of Expression | Level of hypoxia | Altitude | Duration of experiment | Level of expression | Fold change | Experiment details | geographical location | ethnicity of the patients | Control group | Control (Fold change) | Reference (PMID) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENO2 | Rat | Brain cortex | 316 hPa | 8810 m | 1 hour | downregulated | 13.96 ± 0.12 | 2-DE | Southwestern europe | Male albino wistar Rat | 7.04 ±0.03 | Adult male albino Wistar rats weighing 350 g kept at standard conditions | 22961459 |
TF | TF Entrez | Gene | Gene Entrez | Type | PMID | Database |
---|
miRTarBase ID | miRNA | Species (miRNA) | Protein Official Symbol | Human Entrez ID | Species (Target Gene) | Experiments | Support Type | References (PMID) |
---|---|---|---|---|---|---|---|---|
MIRT038722 | hsa-miR-93-3p | Homo sapiens | ENO2 | 2026 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT044208 | hsa-miR-99b-5p | Homo sapiens | ENO2 | 2026 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT440723 | hsa-miR-382-3p | Homo sapiens | ENO2 | 2026 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 24374217 |
ID | GO ID | GO Term | GO Type |
---|---|---|---|
2026 | GO:0006094 | gluconeogenesis | GOTERM_BP_DIRECT |
2026 | GO:0000287 | magnesium ion binding | GOTERM_MF_DIRECT |
2026 | GO:0005515 | protein binding | GOTERM_MF_DIRECT |
2026 | GO:0005829 | cytosol | GOTERM_CC_DIRECT |
2026 | GO:0000015 | phosphopyruvate hydratase complex | GOTERM_CC_DIRECT |
2026 | GO:0043204 | perikaryon | GOTERM_CC_DIRECT |
2026 | GO:0070062 | extracellular exosome | GOTERM_CC_DIRECT |
2026 | GO:0005886 | plasma membrane | GOTERM_CC_DIRECT |
2026 | GO:0043209 | myelin sheath | GOTERM_CC_DIRECT |
2026 | GO:0005615 | extracellular space | GOTERM_CC_DIRECT |
2026 | GO:0004634 | phospholipase D activity | GOTERM_MF_DIRECT |
2026 | GO:0001917 | photoreceptor inner segment | GOTERM_CC_DIRECT |
2026 | GO:0006096 | glycolytic process | GOTERM_BP_DIRECT |
2026 | GO:0061621 | canonical glycolysis | GOTERM_BP_DIRECT |
Human Entrez ID | KEGG ID | KEGG Term |
---|---|---|
2026 | hsa00010 | Glycolysis / Gluconeogenesis |
2026 | hsa01100 | Metabolic pathways |
2026 | hsa01200 | Carbon metabolism |
2026 | hsa01130 | Biosynthesis of antibiotics |
2026 | hsa03018 | RNA degradation |
2026 | hsa01230 | Biosynthesis of amino acids |
2026 | hsa04066 | HIF-1 signaling pathway |
Protein Official Symbol | Human Entrez ID | Disease Name | Disease Id | Disease Semantic Type | Semantic score | DSI | DPI | Disease Type |
---|---|---|---|---|---|---|---|---|
ENO2 | 2026 | Malignant neoplasm of urinary bladder | C0005684 | Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Hepatoma, Morris | C0019207 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Bladder Neoplasm | C0005695 | Neoplastic Process | 0.3 | 0.559 | 0.724 | group |
ENO2 | 2026 | Non-Small Cell Lung Carcinoma | C0007131 | Neoplastic Process | 0.38 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Neoplastic Cell Transformation | C0007621 | Neoplastic Process | 0.3 | 0.559 | 0.724 | phenotype |
ENO2 | 2026 | Hepatoma, Novikoff | C0019208 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Liver Neoplasms, Experimental | C0023904 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.559 | 0.724 | group |
ENO2 | 2026 | Experimental Hepatoma | C0086404 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Neoplasms, Experimental | C0027659 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.559 | 0.724 | group |
ENO2 | 2026 | Leukemia, Myelocytic, Acute | C0023467 | Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Acute Myeloid Leukemia (AML-M2) | C1879321 | Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Acute Myeloid Leukemia, M1 | C0026998 | Neoplastic Process | 0.3 | 0.559 | 0.724 | disease |
ENO2 | 2026 | Schizophrenia | C0036341 | Mental or Behavioral Dysfunction | 0.31 | 0.559 | 0.724 | disease |
Protein Official Symbol | Human Entrez ID | drug_claim_primary_name | drug_name | drug_chembl_id | interaction_types |
---|---|---|---|---|---|
ENO2 | 2026 | FLOXURIDINE | FLOXURIDINE | CHEMBL917 | None |
ENO2 | 2026 | FENRETINIDE | FENRETINIDE | CHEMBL7301 | None |
ENO2 | 2026 | GABAPENTIN | GABAPENTIN | CHEMBL940 | None |
ENO2 | 2026 | INDOMETHACIN | INDOMETHACIN | CHEMBL6 | None |
ENO2 | 2026 | INSULIN | None | None | None |
ENO2 | 2026 | NERVE GROWTH FACTOR | None | None | None |
ENO2 | 2026 | PROPOFOL | PROPOFOL | CHEMBL526 | None |
ENO2 | 2026 | SODIUM BUTYRATE | SODIUM BUTYRATE | CHEMBL62381 | None |
ENO2 | 2026 | STREPTOZOTOCIN | STREPTOZOTOCIN | CHEMBL1651906 | None |
ENO2 | 2026 | TRIIODOTHYRONINE | LIOTHYRONINE SODIUM | CHEMBL1201119 | None |